We also show, here, that in addition to well-established oncogenes such as AR and TP53, mutations in lesser studied genes such as EYA1, CSMD3, FLT4, NCOR2, and PCDH15 are enriched in prostate cancer metastases relative to primary tumors. This evidence concerns the gene FLT4 and prostate carcinoma.